WO2009152500A2 - Procédés et compositions pour médier l'inhibition de l'expression génique - Google Patents

Procédés et compositions pour médier l'inhibition de l'expression génique Download PDF

Info

Publication number
WO2009152500A2
WO2009152500A2 PCT/US2009/047369 US2009047369W WO2009152500A2 WO 2009152500 A2 WO2009152500 A2 WO 2009152500A2 US 2009047369 W US2009047369 W US 2009047369W WO 2009152500 A2 WO2009152500 A2 WO 2009152500A2
Authority
WO
WIPO (PCT)
Prior art keywords
sirna
rnai
target
cell
strand
Prior art date
Application number
PCT/US2009/047369
Other languages
English (en)
Other versions
WO2009152500A3 (fr
WO2009152500A4 (fr
Inventor
Tariq M. Rana
Original Assignee
University Of Massachusetts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Massachusetts filed Critical University Of Massachusetts
Publication of WO2009152500A2 publication Critical patent/WO2009152500A2/fr
Publication of WO2009152500A3 publication Critical patent/WO2009152500A3/fr
Publication of WO2009152500A4 publication Critical patent/WO2009152500A4/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Definitions

  • RNA interference Double stranded RNA (dsRNA) induces a sequence- specific degradation of homologous mRNA in the cellular process known as RNA interference (RNAi). DsRNA-induced gene silencing has been observed in evolutionarily diverse organisms such as nematodes, flies, plants, fungi, and mammalian cells. Although the entire mechanism of RNAi has not yet been elucidated, several key elements have been identified. RNAi is initiated by an ATP-dependent processive cleavage of dsRNA into 21-23 nucleotide short interfering RNAs (siRNAs) by the DICER endonuclease. The siRNAs are then incorporated into an RNA-induced silencing complex (RISC).
  • siRNAs RNA-induced silencing complex
  • This protein and RNA complex is activated by ATP-dependent unwinding of the siRNA duplex.
  • the activated RISC utilizes the antisense strand, also referred to as the guide strand, of the siRNA to recognize and cleave the corresponding mRNA, resulting in decreased expression of the protein encoded by the mRNA.
  • siRNA effectiveness at mediating RNAi varies greatly, and can be affected by a number of factors including, but not limited to, the size of the siRNA, the size and nature of any overhangs, and the specificity of the siRNA. Even siRNAs having optimal length, overhangs and specificity, can be ineffective at mediating RNAi.
  • the present invention is based on the surprising discovery that nucleic acids previously thought to be ineffective in RNAi / gene silencing applications because of having non-canonical ends, e.g., having a non-canonical length ⁇ i.e., being shorter than 21 nucleotides) or non-canonical overhang ⁇ i.e., lacking a 3'dTdT overhang) are as effective as RNAi / gene silencing agents. Accordingly, the invention provides RNAi / gene silencing reagents that bypass the need for 21 nucleotide siRNAs for conducting RNAi.
  • the RNAi agent of the invention comprises an RNA duplex about 16 base paired nucleotides (e.g., 13, 14, 15, 16, 17 or 18 base paired nucleotides), preferably 15 or 16 base-paired nucleotides, and more preferably 16 base paired nucleotides.
  • the RNA duplex forms around 1.5 helical turns.
  • the RNAi agent of the invention may have blunt ends at one or both ends of the duplex.
  • the duplex RNA may comprise single-stranded overhangs at one or both (preferably both) of the 3 'ends of the RNA duplex.
  • the duplex RNA comprises single- stranded overhangs (e.g., single-stranded overhangs of 1-4 nucleotides, preferably 2 nucleotides (e.g., dTdT overhangs)) at both 3' ends of the duplex.
  • single-stranded overhangs e.g., single-stranded overhangs of 1-4 nucleotides, preferably 2 nucleotides (e.g., dTdT overhangs)
  • the invention provides for the separate and temporal administration of single-stranded nucleic acids that are as effective as canonical (duplexed and annealed) siRNA agents for carrying out RNAi / gene silencing.
  • the single- stranded nucleic acids administered separately and over time have the profound advantage of bypassing the interferon response pathway and yet being effective RNAi / gene silencing agents. Because the interferon pathway is triggered by cells exposed to double- stranded nucleic acids, previous RNAi / gene silencing approaches using such agents could not rule out the concomitant activation of this pathway.
  • the invention provides compositions and methods for conducting RNAi / gene silencing both in vitro and in vivo in the absence of an interferon response. This is critical for accurate in vitro screens of gene activities using RNAi and more effective therapeutic applications of RNAi independent of an interferon response.
  • the invention provides compositions and methods for revealing the stoichiometry of RNAi / gene silencing machinery.
  • a titration of double-stranded siRNA nucleic acids having one or more nucleotide modifications, e.g., 2'-O-methylation against an unmodified siRNA, a calculation of per cell amounts of RNAi activity, e.g., RISC activity, can be determined.
  • the invention has several advantages which include, but are not limited to, the following:
  • RNAi agent - providing methods and compositions for carrying out RNAi / gene silencing in the absence of an interferon response by separate and independent administration of an RNAi agent
  • Figure 1 siRNAs with passenger-strand (PS) deletions as triggers for RNAi.
  • B Effects of guide-strand and two-strand deletions on RNAi activity.
  • Figure 2 shows that a 16-bp siRNA with 2 nt 3 '-overhangs targets CDK9 and knocks down CDK9 mRNA more efficiently than a 19-nt siRNA.
  • Figure 3 shows kinetic analysis of CDK9 16-nt RISC.
  • Figure 4 depicts schematics and sequences of siRNAs used in this study to target GFP and CDK9.
  • Figure 5 (A) Depicts schematics of CDK9 19-nt siRNA, 16-nt siRNA, and 29-bp shRNA, and (B) shows that 16-nt siRNA programs more RISC than 19-nt siRNA or 29- bp shRNA.
  • RNA interference refers to a selective intracellular degradation of RNA. RNAi occurs in cells naturally to remove foreign RNAs (e.g., viral RNAs). Natural RNAi proceeds via fragments cleaved from free dsRNA which direct the degradative mechanism to other similar RNA sequences.
  • RNAi can be initiated by the hand of man, for example, to silence the expression of a target gene(s).
  • siRNA having a sequence sufficiently complementary to a target mRNA sequence to direct target- specific RNA interference refers to a siRNA having sequence sufficient to trigger the destruction of the target mRNA by the RNAi machinery or process.
  • small interfering RNA refers to an RNA (or RNA analog) including strand(s) (e.g., sense and/or antisense strands) comprising between about 10-50 nucleotides (or nucleotide analogs) which is capable of directing or mediating RNA interference.
  • siRNA duplex refers to an siRNA having complimentary stands, e.g., a sense strand and antisense strand, wherein the strands are base-paired or annealed (e.g., held together by hydrogen bonds).
  • non-canonical siRNA refers to a siRNA having a structure other than that of a classic or canonical siRNA (i.e., a duplex comprising sense and antisense (or guide) strands of about 20-22 nucleotides in length, aligned such that the 3' ends of the strands extend or overhang the 5' ends of the complementary strands.
  • the non-canonical siRNAs of the invention include an antisense strand of about 19, 20, 21, or 22 nucleotides in length and a shortened or truncated sense strand (e.g., a sense strand of about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 nucleotides in length).
  • the sense strand can be shortened or truncated at the 5' end and aligned such that its 3' end overhangs the 5' end of the antisense strand (e.g., a 2-3 nucleotide overhang (or more), for example a dTdT overhang).
  • the sense strand can be shortened or truncated at the 3' end and aligned such that the 3' end of the antisense strand overhangs its 5' end.
  • the sense strand can be shortened or truncated at the 3' end, the 3' end further comprising 2- 3 non-complementary nucleotides (e.g., dTdT), the sense strand being aligned such that the 3' end of the antisense strand overhangs its 5' end.
  • the sense strand can be shortened or truncated at both ends, the 3' end, optionally, further comprising 2-3 non- complementary nucleotides or more (e.g., dTdT).
  • non-canonical siRNA can also refer to an siRNA having a non- canonical strand length(s) and/or end(s) or overhang(s).
  • a non-canonical strand length is typically less than 21 nucleotides but at least about 10 nucleotides.
  • non- canonical overhang refers to the atypical end or overhang formed when the mixed, duplexed, or single stranded nucleic acids of the invention are aligned or annealed (in vitro or in vivo).
  • the end(s) or overhang(s) are distinguished from a "canonical” (or wild type) end or overhang of an siRNA in that the end or overhang lacks a 2-nucleotide overhang (e.g., dTdT) and/or one or more nucleotides.
  • non-canonical ends include a 5' ends with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more nucleotide deletions (or truncations) and/or no dTdT (also referred to as a 5' non-canonical end) as well as a 3' end with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more nucleotide deletions and/or no dTdT (also referred to as a 3' non-canonical end).
  • Exemplary non-canonical siRNAs are shown in Figs. 3-4.
  • target gene sequence refers to a gene sequence encoding a nucleic acid or polypeptide gene product which can be targeted for degradation, e.g., by RNA interference or a RISC-mediated pathway.
  • the target sequenced may be an artificial, recombinant, or naturally occurring sequence.
  • the sequence encodes a gene product that, when expressed, e.g., at aberrant levels, results in a undesired phenotype, disorder, or disease, in for example, a model organism or human subject.
  • RNAs of the invention that exist or are expressed as separate strands, e.g., a sense single-strand and an antisense single strand that are introduced, e.g., to an extract, cell, or organism as a non-annealed mixture or separately, i.e., unmixed, with, preferably, one strand being introduced first followed after a time interval (e.g., several minutes to about 1 hour or more, e.g., 24, 48, or 72 hours), the second strand.
  • a time interval e.g., several minutes to about 1 hour or more, e.g., 24, 48, or 72 hours
  • priming agent refers to a compound, typically a nucleic acid, e.g., a oligonucleotide or single-stranded nucleic acid, mixture or annealed nucleic acid, siRNA, shRNA, non-canonical siRNAs, or even non-sequence specific nucleic acids, which can be used to enhance or "prime”, “program”, “activate”, or “trigger” an RNAi pathway, e.g., RISC activity, in a cell extract, cell, or organism.
  • the priming agent is introduced or expressed in the cell using art recognized techniques.
  • RISC RNA induced silencing complex
  • RISC activity RNA induced silencing complex activity
  • high level of activated RISC refers to a level of RISC activity, e.g., as measured by target gene degradation, which is sufficiently elevated or above what is usual for a comparable/control extract, cell, or organism.
  • the high level of RISC activity is calculated to be about 0.2 to about 1.9 nM or more for a single cell.
  • the high level of activated RISC is achieved by priming a cell, cell extract, or organism by exposing the cell, cell extract, or organism to a priming agent as described herein. Changes in primed RISC activity as compared to a control result in a fold increase of 1.5, 2, 3, 4, 5, 10, 15, 20, or more.
  • the term "nucleic acid” and "single- stranded nucleic acid” refers to RNA or RNA molecules as well as DNA molecules.
  • RNA refers to a polymer of ribonucleotides.
  • DNA or “DNA molecule” or deoxyribonucleic acid molecule” refers to a polymer of deoxyribonucleo tides.
  • DNA and RNA can be synthesized naturally (e.g., by DNA replication or transcription of DNA, respectively). RNA can be post-transcriptionally modified. DNA and RNA can also be chemically synthesized.
  • DNA and RNA can be single- stranded (i.e., ssRNA and ssDNA, respectively), or multi- stranded (e.g., double stranded, i.e., dsRNA and dsDNA, respectively), i.e., duplexed or annealed.
  • modified nucleotide or “modified nucleic acid(s)” refers to a non- standard nucleotide or nucleic acid, including non-naturally occurring ribonucleotides or deoxyribonucleotides.
  • Preferred nucleotide analogs or nucleic acids are modified at any position so as to alter certain chemical properties, e.g., increase stability of the nucleotide or nucleic acid yet retain its ability to perform its intended function, e.g., have priming and/or RNAi activity.
  • Examples include methylation at one or more bases, e.g., O-methylation, preferably 2' O methylation (2'-0-Me), dyes which can be linked to the nucleic acid to provide for visual detection of the nucleic acid, and biotin moieties which can be used to purify the nucleic acid to which it is attached as well as any associated components bound to the biotinylated nucleic acid.
  • bases e.g., O-methylation, preferably 2' O methylation (2'-0-Me
  • dyes which can be linked to the nucleic acid to provide for visual detection of the nucleic acid
  • biotin moieties which can be used to purify the nucleic acid to which it is attached as well as any associated components bound to the biotinylated nucleic acid.
  • Other examples of modified nucleotides/nucleic acids are described in Herdewijn, Antisense Nucleic Acid Drug Dev., 2000 Aug. 10(4):297-310; U.S
  • a gene "involved" in a disorder includes a gene, the normal or aberrant expression or function of which effects or causes a disease or disorder or at least one symptom of the disease or disorder
  • examining the function of a gene in a cell or organism refers to examining or studying the expression, activity, function or phenotype arising therefrom.
  • Various methodologies of the invention include a step that involves comparing a value, level, feature, characteristic, property, etc. to a "suitable control", referred to interchangeably herein as an "appropriate control”.
  • a “suitable control” or “appropriate control” refers to any control or standard familiar to one of ordinary skill in the art useful for comparison purposes.
  • a “suitable control” or “appropriate control” is a value, level, feature, characteristic, property, etc. determined prior to performing an RNAi methodology, as described herein. For example, a RISC level of activity or amount, target gene level or target gene degradation level, a transcription rate, mRNA level, translation rate, protein level, biological activity, cellular characteristic or property, genotype, phenotype, etc. can be determined prior to introducing a nucleic acid of the invention into a cell, cell extract, or organism.
  • cell refers to any eukaryotic cell which exhibits RNAi activity and includes, e.g., animal cells (e.g., mammalian cells, e.g., human or murine cells), plant cells, and yeast.
  • animal cells e.g., mammalian cells, e.g., human or murine cells
  • plant cells e.g., human or murine cells
  • yeast e.g., cell lines, e.g., mammalian cell lines such as HeLa cells as well as embryonic cells, e.g., embryonic stem cells and collections of cells in the form of, e.g., a tissue.
  • cell extract refers to a Iy sate or acellular preparation of a cell as defined above and can be a crude extract or partially purified as well as comprise additional agents such as recombinant polypeptides, nucleic acids, and/or buffers or stabilizers.
  • organism refers to multicellular organisms such as, e.g., C. elegans,
  • vector refers to a nucleic acid molecule (either DNA or RNA) capable of conferring the expression of a gene product when introduced into a host cell or host cell extract.
  • the vector allows for temporal or conditional expression of one or more nucleic acids of the invention, e.g., a priming agent, single strand, siRNA, non-canonical siRNA, or shRNA.
  • the vector may be episomal or chromosomally (e.g., transgenically) integrated into the host cell genome.
  • the invention features small interfering RNA (siRNA), comprising a sense strand and an antisense strand, the antisense strand having a sequence sufficiently complementary to a target gene sequence to direct target- specific RNA interference (RNAi), wherein the strands, when aligned, form at least one non-canonical overhang or end.
  • siRNA small interfering RNA
  • the non-canonical siRNAs of the invention include an siRNA having a first non- canonical end; an siRNA having a second non-canonical end; an siRNA having a first and a second non-canonical end; an siRNA wherein the sense strand can be shortened or truncated at the 5' end and aligned such that its 3' end overhangs the 5' end of the antisense strand; an siRNA wherein the sense strand can be shortened or truncated at the 3' end and aligned such that the 3' end of the antisense strand overhangs its 5' end; an siRNA wherein the sense strand can be shortened or truncated at the 3' end, the 3' end further comprising 2-3 non-complementary nucleotides, the sense strand being aligned such that the 3' end of the antisense strand overhangs its 5' end; or an siRNA wherein the sense strand can be shortened or truncated at both ends,
  • the invention also provides small interfering RNA (siRNA), comprising a sense strand and an antisense strand, the antisense strand having a sequence sufficiently complementary to a target gene sequence to direct target- specific RNA interference (RNAi), wherein the sense strand and antisense strand are separately and temporally exposed to a cell, cell lysate, or organism.
  • siRNA small interfering RNA
  • the separate administration of each strand where there is a time interval between the introduction of each strand can be performed with canonical or non-canonical siRNA. Time intervals of several minutes to about an hour or more, e.g., 12, 24, 48, and 72 hours or more, are encompassed by the invention.
  • the first strand administered can also function as a priming agent and enhance the level of RISC or RNAi responsiveness of the cell, cell extract, or organism such that the second strand, when introduced, has improved effect.
  • siRNAs of the above aspects can comprise a sense strand of about 21 nucleotides (e.g., 19, 20, 21, or 22 nucleotides) and corresponding antisense strand of at least 10, 11, 12, 13, 14, 15, 16, 17, 18 to 19 nucleotides or an antisense strand of about 21 nucleotides (e.g., 19, 20, 21, or 22 nucleotides) and corresponding sense strand of at least 10, 11, 12, 13, 14, 15, 16, 17, 18 to 19 nucleotides.
  • the siRNA directs target specific interference and bypasses an interferon response pathway.
  • siRNAs comprising a sense strand of 14, 15, or 16 nucleotides are particularly effective.
  • the siRNAs can comprises sense and antisense strands of equal but non-canonical lengths.
  • the antisense and sense strand form a duplex region of about 16 base-paired nucleotides, e.g,. 13, 14, 15, 16, 17 base paired nucleotides.
  • the siRNA comprises a duplex of 16 base paired nucleotides.
  • the siRNA may comprise canonical or non-canonical ends.
  • the siRNA comprises canonical 3'ends of 2 nucleotides, e.g., dTdT 3' overhangs.
  • the gene silencing agents of the invention can be in a pharmaceutically acceptable carrier or liposome.
  • the gene silencing agents of the invention may also be expressed in a cell and therefore encoded in a vector, preferably a vector capable of conditional expression and/or tissue specific expression.
  • the tet operator and operon is a preferred conditional expression system.
  • the invention also provides cells having the above gene silencing agents, for example, as expressed from a vector, maintained episomally or chromosomally integrated (e.g. transgenically) into the genome of the cell.
  • organisms for example transgenic organisms, may be derived or comprise such a cell, and include non- human transgenic organisms such as a transgenic mouse.
  • the invention provides a method of activating target- specific RNA interference (RNAi) in a cell by introducing into the cell a small interfering RNA (siRNA), comprising a sense strand and an antisense strand, the antisense strand having a sequence sufficiently complementary to a target gene sequence to direct target- specific RNA interference (RNAi), wherein the strands, when aligned, form at least one non- canonical overhang.
  • the siRNA is introduced in an amount sufficient for degradation of target mRNA to occur, thereby activating target- specific RNAi in the cell.
  • the sense and antisense strand are introduced separately, and preferably, over a time interval of about 1 hour or more.
  • the RNAi agents e.g., siRNAs, are introduced into the cell by contacting the cell, in particular, with a composition comprising the siRNA and a lipophilic carrier.
  • the siRNA is introduced into the cell by transfecting or infecting the cell with a vector comprising nucleic acid sequences capable of producing the siRNA when transcribed in the cell.
  • the siRNA is introduced into the cell by injecting into the cell a vector comprising nucleic acid sequences capable of producing the siRNA when transcribed in the cell.
  • the vector may further comprise transgene nucleic acid sequences.
  • the invention also encompasses cells made according to the foregoing, in particular, cells of mammalian origin, e.g., embryonic stem cells, or murine or human cells, including human cell lines such as HeLa cells, as well as non-human organisms.
  • the target mRNA specifies the amino acid sequence of a protein involved or predicted to be involved in a human disease or disorder.
  • the invention provides a method of activating target- specific RNA interference (RNAi) in an organism by administering to the organism an siRNA as described above, the siRNA being administered in an amount sufficient for degradation of the target mRNA to occur, thereby activating target- specific RNAi in the organism, e.g., a mammalian organism, including, e.g., a human subject.
  • RNAi target-specific RNA interference
  • the target mRNA specifies the amino acid sequence of a protein involved or predicted to be involved in a human disease or disorder.
  • the invention also provides a method of treating a disease or disorder associated with the activity of a protein specified by a target mRNA in a subject by administering to the subject an siRNA as described above in an amount sufficient for degradation of the target mRNA to occur, thereby treating the disease or disorder associated with the protein.
  • the invention provides methods for deriving information about the function of a gene in a cell or organism by introducing into the cell or organism an siRNA as described above and maintaining the cell or organism under conditions such that target- specific RNAi can occur, determining a characteristic or property of the cell or organism, and comparing the characteristic or property to a suitable control, the comparison yielding information about the function of the gene.
  • the invention provides a method of validating a candidate protein as a suitable target for drug discovery by introducing into a cell or organism an siRNA as described above and maintaining the cell or organism under conditions such that target- specific RNAi can occur, determining a characteristic or property of the cell or organism, and comparing the characteristic or property to a suitable control, the comparison yielding information about whether the candidate protein is a suitable target for drug discovery.
  • the invention provides a kit comprising reagents for activating target- specific RNA interference (RNAi) in a cell or organism, the kit containing an siRNA as described above and instructions for use. Further details for carrying out various aspects of the invention are provided in the following subsections below.
  • RNAi target-specific RNA interference
  • Non-Canonical RNAi Agents Non-Canonical siRNAs
  • the present invention features nucleic acids such as "small interfering RNA molecules" ("siRNA molecules” or “siRNA” but also single and double stranded shRNAs) which can be used as gene silencing agents but also as priming agents for enhancing the RISC activity of a cell.
  • an siRNA molecule of the invention is a duplex consisting of a sense strand and complementary antisense strand, the antisense strand having sufficient complementarity to a target mRNA to mediate RNAi, wherein the molecule is either administered as separate strands (in which case the first strand can serve as a priming agent), as a non-canonical strand(s), or as a non-canonical duplex (either annealed or non-annealed).
  • siRNAs can be from about 10-50 or more nucleotides, i.e., each strand comprises 10-50 nucleotides (or nucleotide analogs).
  • the siRNA molecule has a length from about 15-45 nucleotides. Even more preferably, the siRNA molecule has a length from about 18-25 nucleotides.
  • the siRNA molecules of the invention further have a sequence that is "sufficiently complementary" to a target mRNA sequence to direct target- specific RNA interference (RNAi), as defined herein, i.e., the siRNA has a sequence sufficient to trigger the destruction of the target mRNA by the RNAi machinery or process. Most preferably, the siRNA are non-canonical or administered as separate strands.
  • RNAi agents e.g., RNAi agents, more particularly, non-canonical RNAi agents such as siRNAs
  • an RNAi agent is prepared chemically. Methods of synthesizing RNA molecules are known in the art, in particular, the chemical synthesis methods as de scribed in Verma and Eckstein (1998) Annul Rev. Biochem. 67:99-134.
  • the nucleic acids are produced enzymatically, e.g., by enzymatic transcription from synthetic DNA templates or from DNA plasmids isolated from recombinant bacteria.
  • phage RNA polymerases are used such as T7, T3 or SP6 RNA polymerase (Milligan and Uhlenbeck (1989) Methods Enzymol. 180:51-62).
  • the siRNAs are synthesized either in vivo, in situ, or in vitro.
  • Endogenous RNA polymerase of the cell may mediate transcription in vivo or in situ, or cloned RNA polymerase can be used for transcription in vivo or in vitro.
  • a regulatory region ⁇ e.g., promoter, enhancer, silencer, splice donor and acceptor, polyadenylation
  • Inhibition may be targeted by specific transcription in an organ, tissue, or cell type; stimulation of an environmental condition (e.g., infection, stress, temperature, chemical inducers); and/or engineering transcription at a developmental stage or age or by conditional expression from a vector or transgene having an inducible promoter or operon.
  • a transgenic organism that expresses a nucleic acid priming agent RNA from a recombinant construct may be produced by introducing the construct into a zygote, an embryonic stem cell, or another multipotent cell derived from the appropriate organism.
  • the invention also features small interfering RNAs (siRNAs) that include a sense strand and an antisense strand, wherein the antisense strand has a sequence sufficiently complementary to a target mRNA sequence to direct target- specific RNA interference (RNAi) and wherein the sense strand and/or antisense strand is modified by the substitution of modified nucleotides, such that in vivo stability is enhanced as compared to a corresponding unmodified siRNA.
  • the RNAi agent may be methylated, e.g., 2'O-methylated at one of more bases. Certain modifications confer useful properties to siRNA.
  • modifications may be used to stabilize the first (priming) strand for enhancing RISC activity / RNAi responsiveness in a cell (or cell extract or organism) and improve its intracellular half-life for subsequent receipt of the second strand wherein RNAi / gene silencing can now progress.
  • Certain modifications can also increase the uptake of the siRNA by a cell.
  • functional groups such as biotin are useful for affinity purification of proteins and molecular complexes involved in the RNAi mechanism.
  • the invention also includes methods of testing modified siRNAs for retention of the ability to act as an siRNA (e.g., in RNAi) and methods of using siRNA derivatives, e.g., in order to purify or identify RISC components (see, e.g., PCT/US03/36551; PCT/US03/24595; and PCT/US03/30480).
  • Modifications have the added feature of enhancing properties such as cellular uptake of the siRNAs and/or stability of the siRNAs.
  • Preferred modifications are made at the 2' carbon of the sugar moiety of nucleotides within the siRNA.
  • certain backbone modifications as described herein.
  • chemical modifications that stabilize interactions between base pairs, as described herein. Combinations of substitution are also featured.
  • Preferred modifications maintain the structural integrity of the antisense siRNA-target mRNA duplex.
  • the present invention features modified siRNAs.
  • siRNA modifications are designed such that properties important for in vivo applications, in particular, human therapeutic applications, are improved without compromising the RNAi activity of the siRNA molecules e.g., modifications to increase resistance of the siRNA molecules to nucleases.
  • Modified siRNA molecules of the invention comprise a sense strand and an antisense strand, wherein the sense strand or antisense strand is modified by the substitution of at least one nucleotide with a modified nucleotide, such that, for example, in vivo stability is enhanced as compared to a corresponding unmodified siRNA, or such that the target efficiency is enhanced compared to a corresponding unmodified siRNA.
  • modifications are also useful to improve uptake of the siRNA by a cell.
  • Preferred modified nucleotides do not effect the ability of the antisense strand to adopt A-form helix conformation when base-pairing with the target mRNA sequence, e.g., an A-form helix conformation comprising a normal major groove when base-pairing with the target mRNA sequence.
  • Modified siRNA molecules of the invention can be modified at the 5' end, 3' end, 5' and 3' end, and/or at internal residues, or any combination thereof.
  • Internal siRNA modifications can be, for example, sugar modifications, nucleobase modifications, backbone modifications, and can contain mismatches, bulges, or crosslinks.
  • 3' end, 5' end, or 3' and 5' and/or internal modifications wherein the modifications are, for example, cross linkers, heterofunctional cross linkers, dendrimer, nano-particle, peptides, organic compounds (e.g., fluorescent dyes), and/or photocleavable compounds.
  • the siRNA molecule of the invention comprises one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) end modifications.
  • Modification at the 5' end is preferred in the sense strand, and comprises, for example, a 5 '-propylamine group.
  • Modifications to the 3' OH terminus are in the sense strand, antisense strand, or in the sense and antisense strands.
  • a 3' end modification comprises, for example, 3'- puromycin, 3'-biotin and the like.
  • the siRNA molecule of the invention comprises one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) crosslinks, e.g., a crosslink wherein the sense strand is crosslinked to the antisense strand of the siRNA duplex.
  • Crosslinkers useful in the invention are those commonly known in the art, e.g., psoralen, mitomycin C, cisplatin, chloroethylnitrosoureas and the like.
  • a preferred crosslink of the invention is a psoralen crosslink.
  • the crosslink is present downstream of the cleavage site referencing the antisense strand, and more preferably, the crosslink is present at the 5' end of the sense strand.
  • the siRNA molecule of the invention comprises one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) sugar-modified nucleotides.
  • Sugar- modifed nucleotides useful in the invention include, but are not limited to: 2'-fluoro modified ribonucleotide, 2'-0Me modified ribonucleotide, 2'-deoxy ribonucleotide, T- amino modified ribonucleotide and 2'-thio modified ribonucleotide.
  • the sugar- modified nucleotide can be, for example, 2'-fluoro-cytidine, 2'-fluoro-uridine, 2'-fluoro-adenosine, 2'-fluoro-guanosine, 2'-amino-cytidine, 2'-amino-uridine, 2'-amino-adenosine, 2'-amino- guanosine or 2'-amino-butyryl-pyrene-uridine.
  • a preferred sugar-modified nucleotide is a 2'-deoxy ribonucleotide.
  • the 2'-deoxy ribonucleotide is present within the sense strand and, for example, can be upstream of the cleavage site referencing the antisense strand or downstream of the cleavage site referencing the antisense strand.
  • a preferred sugar- modified nucleotide is a 2'-fluoro modified ribonucleotide.
  • the 2'-fluoro ribonucleotides are in the sense and antisense strands. More preferably, the 2'-fluoro ribonucleotides are every uridine and cytidine.
  • the siRNA molecule of the invention comprises one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) nucleobase-modified nucleotides.
  • Nucleobase-modified nucleotides useful in the invention include, but are not limited to: 5-bromo-uridine, 5-iodo-uridine, 5-methyl-cytidine, ribo-thymidine, 2-aminopurine, 5- fluoro-cytidine, and 5-fluoro-uridine, 2,6-diaminopurine, 4-thio-uridine; and 5-amino- allyl-uridine and the like.
  • the siRNA molecule of the invention comprises one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) backbone-modified nucleotides, for example, a backbone-modified nucleotide containing a phosphorothioate group.
  • the backbone-modified nucleotide is within the sense strand, antisense strand, or preferably within the sense and antisense strands.
  • the siRNA molecule of the invention comprises a sequence wherein the antisense strand and target mRNA sequences comprise one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) mismatches.
  • the mismatch is downstream of the cleavage site referencing the antisense strand. More preferably, the mismatch is present within 1-6 nucleotides from the 3' end of the antisense strand.
  • the siRNA molecule of the invention comprises a bulge, e.g., one or more (e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) unpaired bases in the duplex siRNA.
  • the bulge is in the sense strand.
  • the siRNA molecule of the invention comprises any combination of two or more (e.g., about 2, 3, 4, 5, 6, 7, 8, 9, 10, or more) siRNA modifications as described herein.
  • a siRNA molecule can comprise a combination of two sugar-modified nucleotides, wherein the sugar-modified nucleotides are 2'-fluoro modified ribonucleotides, e.g., 2'-fluoro uridine or 2'-fluoro cytidine, and 2'-deoxy ribonucleotides, e.g., 2'-deoxy adenosine or 2'-deoxy guanosine.
  • the 2'-deoxy ribonucleotides are in the antisense strand, and, for example, can be upstream of the cleavage site referencing the antisense strand or downstream of the cleavage site referencing the antisense strand.
  • the 2'-fluoro ribonucleotides are in the sense and antisense strands. More preferably, the 2'-fluoro ribonucleotides are every uridine and cytidine.
  • the invention is also related to the discovery that certain characteristics of siRNA are necessary for activity and that modifications can be made to an siRNA to alter physicochemical characteristics such as stability in a cell and the ability of an siRNA to be taken up by a cell.
  • the invention includes siRNA derivatives; siRNAs that have been chemically modified and retain activity in RNA interference (RNAi).
  • RNAi RNA interference
  • the invention also includes a dual fluorescence reporter assay (DFRA) that is useful for testing the activity of siRNAs and siRNA derivatives.
  • DFRA dual fluorescence reporter assay
  • the invention includes an siRNA derivative that includes an siRNA having two complementary strands of nucleic acid, such that the two strands are crosslinked, a 3' OH terminus of one of the strands is modified, or the two strands are crosslinked and modified at the 3'OH terminus.
  • the siRNA derivative can contain a single crosslink (e.g., a psoralen crosslink).
  • the siRNA derivative has a biotin at a 3' terminus (e.g., a photocleavable biotin ), a peptide (e.g., a Tat peptide), a nanoparticle, a peptidomimetic, organic compounds (e.g., a dye such as a fluorescent dye), or dendrimer.
  • a biotin at a 3' terminus e.g., a photocleavable biotin
  • a peptide e.g., a Tat peptide
  • nanoparticle e.g., a peptidomimetic
  • organic compounds e.g., a dye such as a fluorescent dye
  • the target gene sequence or mRNA of the invention encodes the amino acid sequence of a cellular protein, e.g., a protein involved in cell growth or suppression, e.g., a nuclear, cytoplasmic, transmembrane, membrane- associated protein, or cellular ligand.
  • the target mRNA of the invention specifies the amino acid sequence of an extracellular protein (e.g., an extracellular matrix protein or secreted protein).
  • Typical classes of proteins are developmental proteins, cancer gene such as oncogenes, tumor suppressor genes, and enzymatic proteins, such as topoisomerases, kinases, and telomerases.
  • the target mRNA molecule of the invention specifies the amino acid sequence of a protein associated with a pathological condition.
  • siRNAs The target RNA cleavage reaction guided by siRNAs (e.g., by siRNAs) is highly sequence specific. In general, siRNA containing a nucleotide sequences identical to a portion of the target gene are preferred for inhibition. However, 100% sequence identity between the siRNA and the target gene is not required to practice the present invention. Thus the invention has the advantage of being able to tolerate sequence variations that might be expected due to genetic mutation, strain polymorphism, or evolutionary divergence. For example, siRNA sequences with insertions, deletions, and single point mutations relative to the target sequence have also been found to be effective for inhibition. Moreover, not all positions of a siRNA contribute equally to target recognition.
  • Mismatches in the center of the siRNA are most critical and essentially abolish target RNA cleavage. Mismatches upstream of the center or upstream of the cleavage site referencing the antisense strand are tolerated but significantly reduce target RNA cleavage. Mismatches downstream of the center or cleavage site referencing the antisense strand, preferably located near the 3' end of the antisense strand, e.g. 1, 2, 3, 4, 5 or 6 nucleotides from the 3' end of the antisense strand, are tolerated and reduce target RNA cleavage only slightly.
  • Sequence identity may determined by sequence comparison and alignment algorithms known in the art. To determine the percent identity of two nucleic acid sequences (or of two amino acid sequences), the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the first sequence or second sequence for optimal alignment).
  • a preferred, non-limiting example of a local alignment algorithm utilized for the comparison of sequences is the algorithm of Karlin and Altschul (1990) Proc. Natl. Acad. ScL USA 87:2264-68, modified as in Karlin and Altschul (1993) Proc. Natl. Acad. ScL USA 90:5873-77. Such an algorithm is incorporated into the BLAST programs (version 2.0) of Altschul, et al. (1990) /. MoI. Biol. 215:403-10.
  • the siRNA may be defined functionally as a nucleotide sequence (or oligonucleotide sequence) that is capable of hybridizing with a portion of the target gene transcript. Examples of stringency conditions for polynucleotide hybridization are provided in Sambrook, J., E.F. Fritsch, and T. Maniatis, 1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, chapters 9 and 11, and Current Protocols in Molecular
  • the invention features methods of assaying the ability of a compound of the invention (e.g., a siRNA, candidate RNAi derivative, modified siRNA, etc.) to modulate (e.g., inhibit) expression of a target RNA using a dual fluorescence system.
  • the assay may be used to determine the amount of improved RISC activity after priming the cell.
  • Other assay systems known in the art that measure the efficacy of an siRNA can be modified as described herein to evaluate whether a modified siRNA is also a priming agent.
  • a compound of the invention (e.g., a priming agent, a siRNA, candidate priming agent, candidate RNAi derivative, modified siRNA, etc.) can be tested for its ability to improve a cell or cell extract RISC activity and responsiveness in inhibiting expression of a targeted gene.
  • candidate RNAi derivatives that can inhibit such expression are identified as siRNA derivatives.
  • Any system in which RNAi activity can be detected can be used to test the activity of a compound of the invention (e.g., a siRNA, candidate priming agent, candidate RNAi derivative, modified siRNA, etc.).
  • a system in which RNAi activity can be detected is incubated in the presence and absence of a compound of the invention (e.g., a siRNA, candidate priming agent, candidate RNAi derivative, modified siRNA, etc.).
  • the invention includes a dual fluorescence reporter gene assay (DFRG assay) that can be used to test a compound of the invention (e.g., a priming agent, candidate priming agent, a siRNA, non-canonical siRNA, candidate RNAi derivative, modified siRNA, etc.).
  • a compound of the invention e.g., a priming agent, candidate priming agent, a siRNA, non-canonical siRNA, candidate RNAi derivative, modified siRNA, etc.
  • the DFRG assay can also be used, for example, to test the ability of these and other types of compounds to inhibit expression of a targeted gene.
  • Technical details of the assay are provided in PCT/US03/30480 which is incorporated by reference in its entirety.
  • nucleic acids Physical methods of introducing nucleic acids include injection of a solution containing the nucleic acid, bombardment by particles covered by the nucleic acid, soaking the cell or organism in a solution of the nucleic acid, or electroporation of cell membranes in the presence of the nucleic acid.
  • a viral construct packaged into a viral particle would accomplish both efficient introduction of an expression construct into the cell and transcription of nucleic acid encoded by the expression construct.
  • Other methods known in the art for introducing nucleic acids to cells may be used, such as lipid-mediated carrier transport, chemical- mediated transport, such as calcium phosphate, and the like.
  • the nucleic acid may be introduced along with components that perform one or more of the following activities: enhance nucleic acid uptake by the cell, inhibit annealing of single strands, stabilize the single strands, or other- wise increase inhibition of the target gene.
  • Nucleic acid may be directly introduced into the cell (i.e., intracellularly); or introduced extracellularly into a cavity, interstitial space, into the circulation of an organism, introduced orally, or may be introduced by bathing a cell or organism in a solution containing the nucleic acid.
  • Vascular or extravascular circulation, the blood or lymph system, and the cerebrospinal fluid are sites where the nucleic acid may be introduced.
  • the cell with the target gene may be derived from or contained in any organism.
  • the organism may a plant, animal, protozoan, bacterium, virus, or fungus.
  • the plant may be a monocot, dicot or gymnosperm; the animal may be a vertebrate or invertebrate.
  • Preferred microbes are those used in agriculture or by industry, and those that are pathogenic for plants or animals.
  • vectors e.g., transgenes encoding a priming agent / siRNA of the invention can be engineered into a host cell or transgenic animal using art recognized techniques.
  • a further preferred use for the agents of the present invention is a functional analysis to be carried out in eukaryotic cells, or eukaryotic non-human organisms, preferably mammalian cells or organisms and most preferably human cells, e.g. cell lines such as HeLa or 293 or rodents, e.g. rats and mice.
  • a suitable priming agent / RNAi agent which is sufficiently complementary to a target mRNA sequence to direct target- specific RNA interference, a specific knockout or knockdown phenotype can be obtained in a target cell, e.g. in cell culture or in a target organism.
  • a further subject matter of the invention is a eukaryotic cell or a eukaryotic non-human organism exhibiting a target gene-specific knockout or knockdown phenotype comprising a fully or at least partially deficient expression of at least one endogenous target gene wherein said cell or organism is transfected with at least one vector comprising DNA encoding an RNAi agent capable of inhibiting the expression of the target gene.
  • RNAi agent capable of inhibiting the expression of the target gene.
  • Gene-specific knockout or knockdown phenotypes of cells or non-human organisms, particularly of human cells or non-human mammals may be used in analytic to procedures, e.g. in the functional and/or phenotypical analysis of complex physiological processes such as analysis of gene expression profiles and/or proteomes.
  • the analysis is carried out by high throughput methods using oligonucleotide based chips.
  • RNAi agents e.g. identifying new RNAi agents, pharmacological agents from a collection of test substances and/or characterizing mechanisms of action and/or side effects of known RNAi agents or pharmacological agents.
  • pharmacological agents e.g. identifying new RNAi agents, pharmacological agents from a collection of test substances and/or characterizing mechanisms of action and/or side effects of known RNAi agents or pharmacological agents.
  • the present invention also relates to a system, for example, a high throughput system (HTS), for identifying and/or characterizing pharmacological agents acting on at least one target protein
  • a system for example, a high throughput system (HTS), for identifying and/or characterizing pharmacological agents acting on at least one target protein
  • HTS high throughput system
  • test compounds of the present invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the 'one-bead one-compound' library method; and synthetic library methods using affinity chromatography selection.
  • the biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds (Lam, K.S. (1997) Anticancer Drug Des. 12:145). Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt et al. (1993) Proc. Natl. Acad. ScL U.S.A.
  • the library is a natural product library, e.g., a library produced by a bacterial, fungal, or yeast culture.
  • the library is a synthetic compound library.
  • Engineered priming / RNAi agents of the invention can be expressed in transgenic animals. These animals represent a model system for the study of disorders that are caused by, or exacerbated by, overexpression or underexpression (as compared to wildtype or normal) of nucleic acids (and their encoded polypeptides) targeted for destruction by the RNAi agents, e.g., siRNAs and shRNAs, and for the development of therapeutic agents that modulate the expression or activity of nucleic acids or polypeptides targeted for destruction.
  • RNAi agents e.g., siRNAs and shRNAs
  • Transgenic animals can be farm animals (pigs, goats, sheep, cows, horses, rabbits, and the like), rodents (such as rats, guinea pigs, and mice), non-human primates (for example, baboons, monkeys, and chimpanzees), and domestic animals (for example, dogs and cats).
  • Invertebrates such as Caenorhabditis elegans or Drosophila can be used as well as non-mammalian vertebrates such as fish (e.g., zebrafish) or birds (e.g., chickens).
  • Engineered RNA precursors with stems of 18 to 30 nucleotides in length are preferred for use in mammals, such as mice.
  • a transgenic founder animal can be identified based upon the presence of a transgene that encodes the new RNA precursors in its genome, and/or expression of the transgene in tissues or cells of the animals, for example, using PCR or Northern analysis. Expression is confirmed by a decrease in the expression (RNA or protein) of the target sequence.
  • Methods for generating transgenic animals include introducing the transgene into the germ line of the animal.
  • One method is by microinjection of a gene construct into the pronucleus of an early stage embryo (e.g., before the four-cell stage; Wagner et al, 1981, Proc. Natl. Acad. Sci. USA 78:5016; Brinster et al, 1985, Proc. Natl. Acad. Sci. USA 82:4438).
  • the transgene can be introduced into the pronucleus by retroviral infection. A detailed procedure for producing such transgenic mice has been described (see e.g., Hogan et al, Manipulating the Mouse Embryo.
  • Clones of the non-human transgenic animals described herein can be produced according to the methods described in Wilmut et al ((1997) Nature, 385:810- 813) and PCT publication Nos. WO 97/07668 and WO 97/07669.
  • the present invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with aberrant or unwanted target gene expression or activity.
  • the subject is primed with a priming agent, and then administered an siRNA for suppressing the expression of an the undesired gene product.
  • treatment is defined as the application or administration of a therapeutic agent (e.g., a RNAi agent or vector or transgene encoding same) to a patient, or application or administration of a therapeutic agent to an isolated tissue or cell line from a patient, who has a disease or disorder, a symptom of disease or disorder or a predisposition toward a disease or disorder, with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve or affect the disease or disorder, the symptoms of the disease or disorder, or the predisposition toward disease.
  • a therapeutic agent e.g., a RNAi agent or vector or transgene encoding same
  • the invention provides a method for preventing in a subject, a disease or condition associated with an aberrant or unwanted target gene expression or activity, by administering to the subject a therapeutic agent (e.g., a RNAi agent or vector or transgene encoding same).
  • a therapeutic agent e.g., a RNAi agent or vector or transgene encoding same.
  • subjects are first treated with a priming agent so as to be more responsive to the subsequent RNAi therapy.
  • Subjects at risk for a disease which is caused or contributed to by aberrant or unwanted target gene expression or activity can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein.
  • Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the target gene aberrancy, such that a disease or disorder is prevented or, alternatively, delayed in its progression.
  • a target gene, target gene agonist or target gene antagonist agent can be used for treating the subject.
  • the appropriate agent can be determined based on screening assays described herein.
  • the invention pertains to methods of modulating target gene expression, protein expression or activity for therapeutic purposes.
  • the modulatory method of the invention involves contacting a cell capable of expressing target gene with a therapeutic agent (e.g., a priming agent, RNAi agent or vector or transgene encoding same) that is specific for the target gene or protein (e.g., is specific for the mRNA encoded by said gene or specifying the amino acid sequence of said protein) such that expression or one or more of the activities of target protein is modulated.
  • a therapeutic agent e.g., a priming agent, RNAi agent or vector or transgene encoding same
  • modulatory methods can be performed in vitro (e.g., by culturing the cell with the agent), in vivo (e.g., by administering the agent to a subject), or ex vivo.
  • subjects are first treated with a priming agent so as to be more responsive to the subsequent RNAi therapy.
  • the present invention provides methods of treating an individual afflicted with a disease or disorder characterized by aberrant or unwanted expression or activity of a target gene polypeptide or nucleic acid molecule. Inhibition of target gene activity is desirable in situations in which target gene is abnormally unregulated and/or in which decreased target gene activity is likely to have a beneficial effect.
  • the therapeutic agents ⁇ e.g., a RNAi agent or vector or transgene encoding same
  • a RNAi agent or vector or transgene encoding same can be administered to individuals to treat (prophylactically or therapeutically) disorders associated with aberrant or unwanted target gene activity.
  • pharmacogenomics i.e., the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug
  • Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug.
  • a physician or clinician may consider applying knowledge obtained in relevant pharmacogenomics studies in determining whether to administer a therapeutic agent as well as tailoring the dosage and/or therapeutic regimen of treatment with a therapeutic agent.
  • compositions suitable for administration typically comprise the nucleic acid molecule, e.g., priming agent, and together or separately, an RNAi agent, e.g., an siRNA agent for carrying out gene silencing, and, optionally, a protein, antibody, or modulatory compound, if appropriate, and a pharmaceutically acceptable carrier.
  • RNAi agent e.g., an siRNA agent for carrying out gene silencing
  • pharmaceutically acceptable carrier is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration.
  • pharmaceutically acceptable carrier is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration.
  • the use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the composition
  • the practice of the present invention employs, unless otherwise indicated, conventional techniques of nucleic acid chemistry, recombinant DNA technology, molecular biology, biochemistry, and cell and cell extract preparation. See, e.g., DNA Cloning, VoIs. 1 and 2, (D.N. Glover, Ed. 1985); Oligonucleotide Synthesis (MJ. Gait, Ed. 1984); Oxford Handbook of Nucleic Acid Structure, Neidle, Ed., Oxford Univ Press (1999); RNA Interference: The Nuts & Bolts ofsiRNA Technology, by D. Engelke, DNA Press, (2003); Gene Silencing by RNA Interference: Technology and Application, by M.
  • RNAs of the invention were chemically synthesized as 2' bis(acetoxyethoxy)- methyl ether-protected oligos by Dharmacon (Lafayette, CO). Synthetic oligonucleotides were deprotected, annealed and purified as described by the manufacturer. Successful duplex formation was confirmed by 20% non-denaturing polyacrylamide gel electrophoresis (PAGE). All siRNAs were stored in DEPC (0.1% diethyl pyrocarbonate)-treated water at -80 0 C. The sequences of GFP or RFP target- specific siRNA duplexes were designed according to the manufacturer's recommendation and subjected to a BLAST search against the human genome sequence to ensure that no endogenous genes of the genome were targeted. Culture and transfection of cells
  • HeLa cells were maintained at 37 0 C in Dulbecco's modified Eagle's medium (DMEM, Invitrogen) supplemented with 10% fetal bovine serum (FBS), 100 units/ml penicillin and 100 ⁇ g/ml streptomycin (Invitrogen). Cells were regularly passaged at sub-confluence and plated 16 hr before transfection at 70% confluency. Lipofectamine (Invitrogen) -mediated transient cotransfections of reporter plasmids and siRNAs were performed in duplicate 6-well plates as described by the manufacturer for adherent cell lines.
  • DMEM Dulbecco's modified Eagle's medium
  • FBS fetal bovine serum
  • penicillin 100 units/ml bovine serum
  • streptomycin 100 ⁇ g/ml streptomycin
  • PBS phosphate buffered saline
  • pEGFP-Cl, pDsRedl-Nl reporter plasmids and 50 nM siRNA were cotransfected into HeLa cells by lipofectamine as described above except that cells were cultured on 35 mm plates with glass bottoms (MatTek Corporation, Ashland MA) instead of standard 6-well plates. Fluorescence in living cells was visualized 48 hours post transfection by conventional fluorescence microscopy (Zeiss). For GFP and RFP fluorescence detection, FITC and CY3 filters were used, respectively.
  • the Dual Fluorescence Efficacy Assay was carried out essentially as described in PCT/US03/30480. Briefly, HeLa cells were maintained at 37 0 C in Dulbecco's modified Eagle's medium (DMEM, Invitrogen) supplemented with 10% fetal bovine serum (FBS), 100 units/ml penicillin, and 100 ⁇ g/ml streptomycin (Invitrogen). Cells were regularly passaged at subconfluence and plated 16 hr before transfection at 70% confluency.
  • DMEM Dulbecco's modified Eagle's medium
  • FBS fetal bovine serum
  • Penicillin 100 units/ml bovine serum
  • streptomycin 100 ⁇ g/ml streptomycin
  • Lipofectamine (Invitrogen)-mediated transient cotransfections of reporter plasmids and siRNAs were performed in duplicate 6-well plates. A transfection mixture containing 0.16 ⁇ g pEGFP-Cl and 0.33 ⁇ g pDsRed2-Nl reporter plasmids (Clontech), various amount of siRNA (From 0.5nM to 40OnM), and 10 ⁇ l lipofectamine in 1 ml serum- reduced OPTI-MEM (Invitrogen) was added to each well. Cells were incubated in transfection mixture for 6 hr and further cultured in antibiotic-free DMEM. Cells were treated under the same conditions without siRNA for mock experiments. At various time intervals, the transfected cells were washed twice with phosphate-buffered saline (PBS, Invitrogen), flash frozen in liquid nitrogen, and stored at -8O 0 C for reporter gene assays.
  • PBS phosphate-buffered saline
  • Fluorescence of GFP in cell lysates was detected by exciting at 488 nm and recording from 498-650 or 504-514 nm.
  • the spectrum peak at 507 or 509 nm represents the fluorescence intensity of GFP.
  • Fluorescence of RFP2 in the same cell lysates was detected by exciting at 558 or 568 nm and recording from 578 to 588 nm or 588 to 650 nm.
  • the spectrum peak at 583 nm represents the fluorescence intensity of RFP2.
  • the fluorescence intensity ratio of target (EGFP) to control (RFP2) fluorophore was determined in the presence of siRNA duplex and normalized to that observed in the mocked treated cells. Normalized ratios less than 1.0 indicates specific interference.
  • Relative RNAi activity represents the percentage of GFP knockdown induced by 50 nM siRNA with passenger-strand deletions relative to the inhibition induced by 50 nM 19-nt wild-type siRNA (designated 100%).
  • Cytoplasmic cell extract preparation and in vitro mRNA cleavage assay To prepare cell extracts, HeLa cells were transfected with 25 nM siRNA, harvested 18 h later with trypsin, and centrifuged at 1000 x g for 5 min at 4°C. The pellets were washed 3x with ice-cold PBS pH 7.2 and lysed by adding 3 packed-cell volumes of lysis buffer (20 mM HEPES pH 7.9, 10 mM NaCl, ImM MgCl 2 , 0.5 M sucrose, 0.2 mM EDTA, 0.5 mM DTT, 0.5 mM PMSF, and 0.35% Triton X-100). Lysis was continued for 10 min on ice.
  • lysis buffer (20 mM HEPES pH 7.9, 10 mM NaCl, ImM MgCl 2 , 0.5 M sucrose, 0.2 mM EDTA, 0.5 mM DTT, 0.5 mM PMSF, and
  • Cytoplasmic extracts in supernatants were prepared by adding 0.11 volumes of cold Buffer B (20 mM HEPES pH 7.9, 10 mM NaCl, 1 mM MgCl 2 , 0.35 M sucrose, 0.2 mM EDTA, 0.5 mM DTT, and 0.5 mM PMSF). Extracts were quick frozen in liquid nitrogen and stored at -80 0 C.
  • Buffer B 20 mM HEPES pH 7.9, 10 mM NaCl, 1 mM MgCl 2 , 0.35 M sucrose, 0.2 mM EDTA, 0.5 mM DTT, and 0.5 mM PMSF.
  • the resulting transcript was 32 P-cap-labeled, as described (Chiu & Rana, 2003).
  • CDK9 target mRNA (10 nM) was incubated for 90 min at 37°C in the presence of 4DL cytoplasmic extract ,1 mM ATP, 0.2 mM GTP, 1U/DL RNasin (Promega), 30 Dg/ml creatine kinase, 25 mM creatine phosphate, 2 mM MgCl 2 , 20 mM NaCl. Buffer D (I M KCl, 20 mM HEPES pH 7.9, 10% glycerol, 0.2 mM EDTA) was added to a final reaction volume of 20 Dl.
  • Buffer D I M KCl, 20 mM HEPES pH 7.9, 10% glycerol, 0.2 mM EDTA
  • Cleavage reactions were stopped by adding 9 volumes of proteinase K buffer (200 mM Tris-HCl pH 7.5, 25 mM EDTA, 300 mM NaCl, and 2% [w/v] SDS). Proteinase K (Ambion) was added to a final concentration of 0.6 mg/ml. Reactions were incubated for 15 min at 37°C. Cleavage products were isolated by phenol/chloroform/isoamyl alcohol (25:24:1) extraction and ethanol precipitation, and resolved on a 6.5% polyacrylamide-7 M urea gel.
  • proteinase K buffer 200 mM Tris-HCl pH 7.5, 25 mM EDTA, 300 mM NaCl, and 2% [w/v] SDS. Proteinase K (Ambion) was added to a final concentration of 0.6 mg/ml. Reactions were incubated for 15 min at 37°C. Cleavage products were isolated by phenol/chloroform
  • RNAi agents comprising a 16 nt duplex are as effective at generating activated RISC complexes and inducing gene silencing as RNAi agents comprising a 19 nucleotide duplex.
  • siRNA duplexes to target green fluorescent protein (GFP) and to have a 19-nt guide strand plus dTdT and a passenger strand harboring deletions at the 5'- or 3 '-ends (PD-I to PD- 14) (Fig IA and Fig4).
  • RNAi activity of these siRNA duplexes was quantitatively analyzed by a dual fluorescence reporter system (Chiu & Rana, 2002, 2003). Wild-type 19-nt siRNA (50 nM) silenced 92% of GFP expression in HeLa cells 48 h post-transfection; this RNAi activity is denoted as 100% in Fig 1 for comparison with the activity of other siRNA sequences. Analysis of 19-nt siRNAs with 5 '-passenger-strand (PS) deletions showed that a 16-nt siRNA with PS deletions (PD-I) induced RNAi with -75% efficiency whereas two other siRNAs with PS deletions, PD-2 and PD-3, did not exhibit RNAi activity.
  • PS '-passenger-strand
  • siRNA duplexes were synthesized with deletions at both the 5'- and 3 '-ends of the passenger strand and tested their RNAi activity.
  • PD-10 a 16-nt duplex with a passenger strand at positions 3-18 was highly efficient at knocking down GFP (-92%), but an 11-nt duplex with a passenger strand at positions 5-15 (PD-14) was nonfunctional, and adding dTdT to the shorter duplex (PD- 13) did not improve its RNAi function (Fig IA).
  • siRNAs with a 15- or 14-nt passenger strand.
  • PD-Il with a 15-nt passenger strand exhibited -85% RNAi activity, whereas the RNAi activity for PD-12 with a 14-nt passenger strand dropped to -53%.
  • RNAi activity for PD-12 with a 14-nt passenger strand dropped to -53%.
  • dsRNA duplexes (GD-I to GD-3) were used that harbored a 19-nt plus 3' dTdT passenger strand and a guide strand truncated from the 5'- and/or 3'-ends (Fig IB).
  • GD-I exhibited less efficient RNAi (-59%). This loss of function may have been due to the 5-nt passenger- strand overhang created by deleting nucleotides 1-3 of the guide strand, since increasing 3 '-overhang length is known to negatively affect RNAi
  • GD-3 also showed intermediate RNAi activity (-57%), again likely due to the loss of function contributed by the 4-nt passenger strand 3'-overhang. These results indicate that a 19-nt passenger strand and a 16-nt guide strand can induce RNAi. Surprisingly, GD-2 did not exhibit RNAi activity, suggesting that the 17 th to 19 th nucleotides from the 5 '-end of the guide strand may be important for RISC assembly or target mRNA recognition.
  • the 16-nt GFP siRNA (PGD-I) exhibited wild-type (WT) levels of GFP knockdown (Fig IB), indicating that a 16-nt siRNA is as efficient as a 19-nt siRNA at triggering RNAi in vivo.
  • WT wild-type
  • Fig IB wild-type levels of GFP knockdown
  • 16-nt siRNA targeting CDK9 was synthesized based on the published 19-nt siRNA sequence (Brown et al., 2005) (Fig 2A).
  • This 16-nt CDK9 siRNA was evaluated for RNAi efficacy by transfecting it into HeLa cells in parallel with 19-nt WT siRNA and measuring CDK9 mRNA and protein levels at 48h post transfection.
  • the 16-nt siRNA was shown by quantitative PCR to knock down CDK9 mRNA with higher efficiency (-90%) than 19-nt siRNA (-75%) (Fig 2B). Consistent with this result, endogenous CDK9 protein was shown by immunoblot analysis to be reduced in HeLa cells transfected with 16-nt or 19-nt siRNA (Fig 2C).
  • RISC was programmed by transfecting HeLa cells with 19-nt or 16-nt CDK9 siRNA, preparing cell extracts, and measuring the ability of activated siRNA-programmed RISCs (siRISCs) to cleave added 150-nt 32 P-cap- labeled CDK9 mRNA target.
  • siRISCs activated siRNA-programmed RISCs
  • the 16-nt siRNA RISC exhibited a much higher cleavage activity with equal amounts of cell extracts, suggesting that 16-nt siRNA is a more potent RNAi trigger.
  • the cleavage product of CDK9 16-nt siRNA RISC revealed that the cleavage site had shifted 3 nt (Fig 2D; compare lanes 1 and 2 and arrows), consistent with previous studies (Elbashir et al., 2001b) and reflecting the new position of the 5'-end of the guide strand after truncating 3 nt.
  • the substrate concentration dependence of CDK9 16-nt RISC cleavage activity was examined by varying the amount of target mRNA (2 nM, 10 nM, 20 nM, and 5OnM) in a fixed- volume (20 ul) reaction with a constant amount of cell extract programmed with 16-nt RISC.
  • the efficiency of RISC target cleavage increased with target mRNA concentration, saturating at higher concentrations (Figs 3 A, 3B).
  • the K m and V max of CDK9 16-nt RISC target cleavage were determined by nonlinear fitting of substrate concentration versus initial velocity to the Michaelis-Menton equation (Fig 3B).
  • the concentration of 16-nt RISC was determined by blocking the cleavage activity of RISC with varying concentrations of 2'-O-methyl oligonucleotides complementary to the guide strand 16-nt siRNA and measuring the IC 50 (Brown et al., 2005) (Fig 3C and Fig 5). These results indicate that the 16-nt RISC is a multiple-turnover enzyme that recognizes and cleaves its target with classic Michaelis-Menton kinetics.
  • the K m for 16- nt RISC is 17.94 nM and its V max is 9.72 x 10 "3 nM/sec (Fig 3D).
  • the concentration of 16-nt RISC programmed in HeLa cells was 18.26 nM, indicating that 16-nt siRNA programmed ⁇ 7x more RISC than 19-nt siRNA (2.5 nM) (Fig 3C;(Brown et al., 2005)).
  • rate constant (K cat ) determination showed that RISC programmed with 16-nt RNA was not catalytically more efficient than the 19-nt RISC (Fig 3D).
  • K cat rate constant

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention concerne des procédés permettant de conduire une ARNi au moyen de siARN qui sont successivement administrés sous la forme d'oligonucléotides simple brin. Les SiARN peuvent être canoniques ou avoir des extrémités non canoniques. Les compositions et les procédés selon l'invention peuvent court-circuiter l'activation des voies de l'interféron tout en activant toujours efficacement et spécifiquement l'ARNi/inhibition de l'expression génique. Dans un autre mode de réalisation, les siARN selon l'invention sont modifiés pour permettre le calcul de certaines activités ARNi, par exemple, l'activité RISC. Cette invention concerne également des procédés d'utilisation des compositions dans des applications de recherche, diagnostiques, et thérapeutiques.
PCT/US2009/047369 2008-06-13 2009-06-15 Procédés et compositions pour médier l'inhibition de l'expression génique WO2009152500A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6153808P 2008-06-13 2008-06-13
US61/061,538 2008-06-13

Publications (3)

Publication Number Publication Date
WO2009152500A2 true WO2009152500A2 (fr) 2009-12-17
WO2009152500A3 WO2009152500A3 (fr) 2010-03-18
WO2009152500A4 WO2009152500A4 (fr) 2010-05-20

Family

ID=41268272

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/047369 WO2009152500A2 (fr) 2008-06-13 2009-06-15 Procédés et compositions pour médier l'inhibition de l'expression génique

Country Status (1)

Country Link
WO (1) WO2009152500A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015051044A3 (fr) * 2013-10-04 2015-07-02 Novartis Ag Formats inédits pour composés organiques utiisables en interférence arn
WO2015051366A3 (fr) * 2013-10-04 2015-07-02 Novartis Ag Formats inédits pour composés organiques utilisables en interférence arn
US10392619B2 (en) 2009-10-12 2019-08-27 Larry J. Smith Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
WO2021117009A3 (fr) * 2019-12-11 2021-08-26 Moore Tara Silençage spécifique d'allèle de gène induit par le facteur de croissance transformant bêta avec mutation r124h à l'aide d'arn interférant court

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005079533A2 (fr) * 2004-02-17 2005-09-01 University Of Massachusetts Procedes et compositions de mediation du silençage genique
US20080020990A1 (en) * 2003-05-30 2008-01-24 Nippon Shinyaku Co., Ltd. Oligo Double-Stranded Rna Inhibiting the Expression of Bcl-2 and Pharmaceutical Composition Containing the Same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080020990A1 (en) * 2003-05-30 2008-01-24 Nippon Shinyaku Co., Ltd. Oligo Double-Stranded Rna Inhibiting the Expression of Bcl-2 and Pharmaceutical Composition Containing the Same
WO2005079533A2 (fr) * 2004-02-17 2005-09-01 University Of Massachusetts Procedes et compositions de mediation du silençage genique

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CZAUDERNA FRANK ET AL.: "Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells" NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 31, no. 11, 1 June 2003 (2003-06-01), pages 2705-2716, XP002404762 ISSN: 0305-1048 *
ELBASHIR S M ET AL: "Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate" EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 20, no. 23, 3 December 2001 (2001-12-03), pages 6877-6888, XP002225998 ISSN: 0261-4189 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10392619B2 (en) 2009-10-12 2019-08-27 Larry J. Smith Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
US11359201B2 (en) 2009-10-12 2022-06-14 Larry J. Smith Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
WO2015051044A3 (fr) * 2013-10-04 2015-07-02 Novartis Ag Formats inédits pour composés organiques utiisables en interférence arn
WO2015051366A3 (fr) * 2013-10-04 2015-07-02 Novartis Ag Formats inédits pour composés organiques utilisables en interférence arn
US9988627B2 (en) 2013-10-04 2018-06-05 Novartis Ag Formats for organic compounds for use in RNA interference
WO2021117009A3 (fr) * 2019-12-11 2021-08-26 Moore Tara Silençage spécifique d'allèle de gène induit par le facteur de croissance transformant bêta avec mutation r124h à l'aide d'arn interférant court

Also Published As

Publication number Publication date
WO2009152500A3 (fr) 2010-03-18
WO2009152500A4 (fr) 2010-05-20

Similar Documents

Publication Publication Date Title
US20060069050A1 (en) Methods and compositions for mediating gene silencing
US20050273868A1 (en) Methods and compositions for enhancing RISC activity in vitro and in vivo
JP4339852B2 (ja) 遺伝子サイレンシングに関する方法および組成物
JP6069096B2 (ja) より新規形態の干渉ｒｎａ分子
Chen et al. A member of the polymerase β nucleotidyltransferase superfamily is required for RNA interference in C. elegans
EP2488641B1 (fr) Adn surenroulé en minicercle pour applications en thérapie génique
JP2013516197A (ja) 性ホルモン結合グロブリン（ｓｈｂｇ）に対する天然アンチセンス転写物の阻害による性ホルモン結合グロブリン（ｓｈｂｇ）関連疾患の治療
KR20220104677A (ko) 스플라이싱 및 단백질 발현을 조절하기 위한 조성물 및 방법
JP2010527243A (ja) 低分子干渉ＲＮＡ（ｓｉＲＮＡ）を用いた記憶形成に関わる遺伝子の同定方法
JP2013516175A (ja) インスリン受容体基質２（ｉｒｓ２）および転写因子３（ｔｆｅ３）に対する天然アンチセンス転写物の阻害によるインスリン受容体基質２（ｉｒｓ２）関連疾患の治療
US20190300882A1 (en) Methods of treating neuroblastoma and reagents therefor
WO2009152500A2 (fr) Procédés et compositions pour médier l'inhibition de l'expression génique
JPWO2006054788A1 (ja) 特定のｍＲＮＡの翻訳を制御する化合物のスクリーニング方法
Muller et al. An Efficient method for electroporation of small interfering RNAs into ENCODE project tier 1 GM12878 and K562 cell lines
EP1813289B1 (fr) Composition médicinale pour le traitement du cancer ou du diabète
JP4705370B2 (ja) より新規形態の干渉ｒｎａ分子
US20230383293A1 (en) Modified functional nucleic acid molecules
US20220298512A1 (en) Sirna sequences targeting the expression of human genes jak1 or jak3 for a therapeutic use
AU2004256322B2 (en) siRNA expression system
Marinaroà et al. METHODOLOGICAL CHALLENGES IN FUNCTIONAL INVESTIGATION AND THERAPEUTIC USE OF
Marinaro et al. Methodological Challenges in Functional Investigation and Therapeutic Use of microRNAs
Hall Application of RNAi in biomedical research
Broderick Cooperativity in Mammalian RNA Silencing: A Dissertation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09736710

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09736710

Country of ref document: EP

Kind code of ref document: A2